COTA Inc. has announced a new partnership with Guardant Health Inc. to accelerate the development of new cancer therapies using real-world clinicogenomic data and AI analytics. This collaboration aims to provide research scientists with extensive datasets to better understand correlations between molecular biomarkers, treatment decisions, and clinical outcomes.